Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 0.00 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| OncoSec Medical Incorporated (CE) | ONCSQ | OTCMarkets | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.0003 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.0003 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0.00 | - | 0.000001 - 0.23 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 0.0003 | USD |
OncoSec Medical Incorporated (CE) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 1.79k | 5.96M | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
OncoSec Medical (CE) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/13/2024 | 13:30 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ONCSQ Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.0003 | 0.0003 | 0.0003 | 0.0003 | 192 | 0.00 | 0.00% |
| 1 Month | 0.000001 | 0.0003 | 0.000001 | 0.0001602 | 1,500 | 0.0003 | 29,900.00% |
| 3 Months | 0.0001 | 0.0003 | 0.000001 | 0.0000857 | 4,434 | 0.0002 | 200.00% |
| 6 Months | 0.000001 | 0.0003 | 0.000001 | 0.0000935 | 6,951 | 0.0003 | 29,900.00% |
| 1 Year | 0.18 | 0.23 | 0.000001 | 0.1105852 | 59,602 | -0.1797 | -99.83% |
| 3 Years | 0.18 | 0.23 | 0.000001 | 0.1105852 | 59,602 | -0.1797 | -99.83% |
| 5 Years | 0.18 | 0.23 | 0.000001 | 0.1105852 | 59,602 | -0.1797 | -99.83% |
OncoSec Medical (CE) Description
| OncoSec Medical Incorporated is a biopharmaceutical company developing its proprietary DNA-based intratumoral cancer immunotherapy technology, ImmunoPulse. OncoSec Medical's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based agents that target tumor-induced immune subversion pathways. ImmunoPulse is a therapeutic approach that utilizes an electroporation delivery device in combination with DNA-encoded immune target modulators to treat cancer. Clinical studies of ImmunoPulse have demonstrated that the therapy is well-tolerated and preliminary evidence of anti-tumor activity has been observed, including the potential to initiate an immune response without the toxicities associated with systemic treatments. OncoSec Medical's lead program is evaluating ImmunoPulse for the treatment of metastatic melanoma. A Phase 2b study is in development to evaluate ImmunoPulse in combination with a checkpoint inhibitor, called anti-PD1 (pembrolizumab), for the treatment of metastatic melanoma and is being conducted in collaboration with several prominent academic medical centers. The company is also focused on identifying and developing new DNA-encoded proteins that target key pathways of tumor-induced immune subversion, investigating additional tumor indications, and evaluating other combination-based immunotherapy approaches. For more information, please visit www.oncosec.com. |
